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carcinoma patients, one-year survival rate and median survival time 
were signiﬁcantly higher in arm A than in arm B (64.7% vs 26.3%, 
P=0.021) and (12.5 months vs 8.7months, P=0.033) respectively. Nau-
sea/vomiting occurred more frequently in arm A than in arm B(67.74% 
vs 40.0%, P=0.030). There was no statistically difference between two 
groups in the other side-effects. 
Conclusions: The regimen of NP combined with COX-2 inhibitor 
celecoxib was effective and tolerable as the ﬁrst-line chemotherapy in 
advanced NSCLC.In the subgroup of adenocarcinoma, The one-year 
survival rate and median survival time of those treated with NP com-
bined with celecoxib were signiﬁcantly higher.
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Purpose: Mutations in epidermal growth factor receptor (EGFR) are 
considered as a strong predictive marker for the response to EGFR ty-
rosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) 
patients. This study by Korean Cancer Study Group (KCSG) was con-
ducted to determine the clinical implications of EGFR gene mutation, 
increased gene copy number and protein over-expression in Korean 
patients with advanced NSCLC who were treated with erlotinib. 
Patients and Methods: A total of 120 patients received erlotinib 
(TARCEVA®) at a dose of 150mg daily between January 2005 and 
February 2006. Ninety-two tissue samples obtained from these patients 
were analyzed for EGFR mutation (exon 18-21) and K-ras mutation, 
88 samples for EGFR gene ampliﬁcation by real-time PCR, and 77 
samples for EGFR protein expression by means of immunohistochemi-
cal staining. 
Results: Twenty-four out of 92 patients (26.1%) had EGFR muta-
tions in exon 18, 19, and 21, most commonly in exon 19 (75% 18/24). 
A higher frequency was noted in female patients (40.0% vs 17.5%, 
p=0.017). Higher rate of response to erlotinib was noted in patients 
with EGFR mutations compared to wild type (58.3% vs 16.2%, 
p<0.0001). With 14.5 month of median follow-up duration, time to 
progression (TTP) and overall survival (OS) were signiﬁcantly longer 
in patients with mutations than those without mutations (p=0.003, 
p=0.042). Increased EGFR gene copy number was found in 40.9% 
(36/88) of the PCR samples. Patients with increased gene copy num-
ber achieved higher rate of response to erlotinib (38.9% vs 17.3%, 
p=0.023). Also patients with high gene copy number showed longer 
TTP (p<0.0001) and OS (p=0.022). Forty-six out of 75 patients (72%) 
positively expressed the EGFR protein, although there was no relation-
ship between the EGFR expression and the response to erlotinib, TTP 
or OS. 
Conclusion: Our ﬁndings indicate that both EGFR mutation and EGFR 
gene ampliﬁcation were shown to be important predictive markers not 
only for achieving clinical response to erlotinib but also for the prolon-
gation of overall survival in Korean patients with advanced NSCLC.
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Background: Erlotinib is the ﬁrst orally available selective EGFR 
tyrosine-kinase inhibitor that improves survival in 2nd and 3rd line 
therapy for NSCLC. More than 50% of newly patients diagnosed with 
NSCLC are over the age of 65 and 30-40% over the age of 70. Several 
studies suggested an increased risk of toxicity in patients >70 years 
when treated with chemotherapy due to reduced organ function and the 
presence of comorbidities. Single agent treatment is considered an op-
tion of choice in this subset of patients. We have evaluated the efﬁcacy 
of Erlotinib in elderly patients (≥70 yrs) with advanced or metastatic 
NSCLC.
Methods: The TargeT trial was an open-label multicenter study carried 
out in 103 Spanish institutions. Elderly patients (70 and older) included 
in this trial were eligible for this analysis. All patients had conﬁrmed 
advanced or metastatic NSCLC, PS 0-2 and adequate organ function, 
and had received prior chemotherapy or not. Patients were treated with 
Erlotinib 150 mg/day po until disease progression or withdrawal.
Results: From April 2004 to March 2006, 1.796 patients (p) were 
included in the TargeT trial. By the time of this analysis, data from 570 
p (≥ 70 years old) were available. Demographics: males 73.9%; median 
age: 75 yrs. [range 70-95]; stage IV: 76.1%; PS 0-1: 72.1%; histology: 
adenocarcinoma 51.4%, SCC 26.7%, LCC 15.6%, other 6.3%. Current/
ever smokers 73.0%; 1st/2nd/3rd or further: 46.7%/36.3%/17.0%. 
In the evaluable population for response (302 p) 23.8% reached partial 
response and 2 p complete response (0.7%). Of interest, both complete 
responses were detected in p treated with Erlotinib in the ﬁrst line set-
ting. Control disease rate was 67.6%. In the univariate analysis RR was 
signiﬁcantly higher among women (51.5%; p<0.0001), non-smokers 
(51.0%; p<0.0001), adenocarcinomas (31.8%; p=0.003) and those treat-
ed with Erlotinib in the ﬁrst line setting (30.7% vs. 18.4%; p=0.01). 
In the ITT population, median time to progression (TTP) was 5.4 
months [95% CI 4.5-6.5] and median survival was 6.2 months [95% 
CI 5.2-7.1]. In the univariate analysis, predictive factors for longer 
